Table 2.
Criteria for evaluation of paediatric ARV products included in IATT optimal formular [18]
| Criterion | Definition | |
|---|---|---|
| Meets WHO requirements | • | Included in the latest WHO guidelines for paediatric treatment |
| Allows for widest range of dosing options | • | Allows for flexible dosing across multiple weight-bands and ages |
| Approved by SRA/WHO PQ | • | Availability of at least one SRA-approved product |
| User friendly | • | Easy for healthcare worker to prescribe |
| • | Easy for caregivers to administer | |
| • | Supports adherence | |
| Optimizes supply chain management | • | Easy to transport |
| • | Easy to store | |
| • | Easy to distribute | |
| Available for resource-limited settings | • | Product is licensed/registered for use in resource-limited settings |
| • | Reliable supply of product | |
| Comparative cost | • | Cost should not be a deciding factor; however comparative cost of formulations of the same drug/drug combination should be considered |
SRA, stringent regulatory agencies; WHO PQ, WHO pre-qualification programme.